News | April 15, 2014

Concerning Number of Children Have Elevated Cholesterol

Findings underscore the importance of universal pediatric cholesterol screening, authors say

April 15, 2014 — Roughly one out of three children screened for high cholesterol between the ages of 9 and 11 has borderline or high cholesterol, potentially placing them at greater risk for future cardiovascular disease, according to research to be presented at the American College of Cardiology’s 63rd Annual Scientific Session.

In one of the largest clinical studies of outpatient pediatric clinic visits to date, researchers examined the medical records of 12,712 children who had screening for cholesterol levels as part of a routine physical exam within the Texas Children’s Pediatrics Associates clinics, the nation’s largest pediatric primary care organization. Of these, 4,709, or 30 percent, had borderline or elevated total cholesterol as defined by the National Cholesterol Education Program.

“The sheer number of kids with abnormal lipid profiles provides further evidence that this is a population that needs attention and could potentially benefit from treatment,” said Thomas Seery, M.D., pediatric cardiologist at Texas Children’s Hospital, assistant professor of Pediatrics at Baylor College of Medicine, and the lead investigator of the study. “But we can only intervene if we diagnose the problem.”

While cardiovascular disease in children is rare, the presence of certain risk factors in childhood can increase the chances of developing heart disease as an adult. Previous studies have demonstrated that atherosclerosis — a hardening and narrowing of the arteries — can begin in childhood.

“We know that higher levels of, and cumulative exposure to, high cholesterol is associated with the development and severity of atherosclerosis,” Seery said. “If we can identify and work to lower cholesterol in children, we can potentially make a positive impact by stalling vascular changes and reducing the chances of future disease.” He said that this is especially important amid the growing obesity epidemic, which is resulting in a larger population of children with dyslipidemia, an abnormal amount of cholesterol or fats in the blood.

In this study, researchers also found that boys were more likely than girls to have elevated total cholesterol, low-density lipoprotein (LDL), or “bad” cholesterol, and triglycerides, while girls had lower high-density lipoprotein (HDL) or “good” cholesterol. Obese children were more likely to have elevated total cholesterol, LDL and triglycerides, with lower HDL in comparison to non-obese children. Average total cholesterol, LDL, non-HDL and HDL were all within the normal range, 162 mg/dL, 92 mg/dL, 113 mg/dL and 52 mg/dL, respectively; mean triglycerides were borderline or abnormal (103 mg/dL). Similar to a recent, unrelated study of adult minority groups, 9- to 11-year-old Hispanic children in this study were more likely to have elevated triglycerides and lower HDL when compared to non-Hispanics.

The authors said they hope their findings will give added weight to guidelines sponsored by the National Heart Lung and Blood Institute and endorsed by the American Academy of Pediatrics that call for universal cholesterol screening of children between the ages of 9 and 11 years and, again between 17 and 21 years of age. Despite these recommendations, some practitioners remain hesitant.

“There is concern by some in the medical community that children will be started on medication unnecessarily,” Seery said, emphasizing that adopting a healthy diet and engaging in routine physical activity are first-line therapies for children with abnormal cholesterol levels.

He added that cholesterol-lowering medications are typically needed in one to two percent of children with dyslipidemia, primarily in those with very high cholesterol resulting from a genetic lipoprotein disorder. Genetic lipoprotein disorders, such as familial hypercholesterolemia, result in very high cholesterol levels that can be detected in childhood but are felt to be underdiagnosed, he said.

“Kids need to have their cholesterol panel checked at some point during this timeframe [9 to 11 years old],” Seery said. “In doing so, it presents the perfect opportunity for clinicians and parents to discuss the importance of healthy lifestyle choices on cardiovascular health. Our findings give a compelling reason to screen all kids’ blood cholesterol.”

Because the universal pediatric screening recommendations rolled out at the end of 2011, during the second year of this study, Seery said a potential study limitation is that it is unknown if testing was ordered in a universal manner or selectively based upon individual risk factors or a family history of premature cardiac disease. Recent studies have demonstrated that screening based on family history alone risks missing a large number of children who have dyslipidemia. In addition, the study population was limited to the region in and around Houston.

Further research is needed in order to determine the rate at which primary care providers are following the guidelines since the roll out in 2011, Seery said.

For more information: www.cardiosource.org

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Overlay Init